Grifols is a global healthcare company based in Spain, specializing in the production and commercialization of plasma-derived products. The company operates primarily through three segments: Bioscience, Hospital, and Diagnostic. In the Bioscience segment, Grifols focuses on the research, development, and manufacturing of plasma derivatives, which are essential for various medical treatments. The Diagnostic segment develops and markets diagnostic products for laboratory analysis, catering to hospital blood banks and transfusion centers. Grifols has significantly expanded its product portfolio through strategic acquisitions, including Talecris in 2011 and Biotest in 2022. As of 2023, the biopharma segment represented the majority of the company's sales, with diagnostics contributing a smaller portion.
GigaGen, Inc. is a biopharmaceutical company focused on developing innovative antibody therapies for cancer and immune deficiencies. Founded in 2010 and based in South San Francisco, California, GigaGen employs advanced technologies such as microfluidics, bioinformatics, sequencing, and genetic engineering to analyze B and T cell repertoires. This enables the identification of full-length, natively paired antibodies and T cell receptors. The company is advancing a pipeline that includes novel oncology antibody drug combinations and the first recombinant polyclonal hyperimmune gammaglobulin. GigaGen's proprietary discovery technology allows for the rapid characterization of cells within complex immune systems, which facilitates the selection of drug targets and the identification of potential drug candidates, ultimately enhancing preclinical efficacy assessments.
Alkahest, Inc. is a clinical stage biopharmaceutical company based in San Carlos, California, founded in 2014. The company focuses on developing therapies derived from blood to address neurological diseases, particularly those associated with aging, such as Alzheimer’s disease and Parkinson’s disease. Alkahest's research has revealed that factors present in the blood plasma of younger mice can potentially reverse cognitive deficits in aging and Alzheimer’s disease models. Collaborating with Grifols, a global healthcare company known for its plasma therapies, Alkahest aims to enhance health and vitality through innovative treatments that target the effects of aging.
MedKeeper provide a suite of fast, flexible, and economical applications for hospital pharmacies. Their secure, hosted applications are used by hundreds of hospitals and medical centers to promote pharmacy communications, compliance and productivity.
GigaGen, Inc. is a biopharmaceutical company focused on developing innovative antibody therapies for cancer and immune deficiencies. Founded in 2010 and based in South San Francisco, California, GigaGen employs advanced technologies such as microfluidics, bioinformatics, sequencing, and genetic engineering to analyze B and T cell repertoires. This enables the identification of full-length, natively paired antibodies and T cell receptors. The company is advancing a pipeline that includes novel oncology antibody drug combinations and the first recombinant polyclonal hyperimmune gammaglobulin. GigaGen's proprietary discovery technology allows for the rapid characterization of cells within complex immune systems, which facilitates the selection of drug targets and the identification of potential drug candidates, ultimately enhancing preclinical efficacy assessments.
Hologic - NAT donor screening unit
Acquisition in 2017
Hologic - NAT donor screening unit engages in research, development and manufacture of assays and instruments based on NAT (Nucleic Acid Testing) technology for transfusion and transplantation screening
Singulex, Inc. is an immunodiagnostics and biotechnology company that specializes in single molecule counting (SMC) technology for clinical diagnostics and scientific research. The company has developed the Sgx Clarity System, an in vitro diagnostics platform capable of detecting low abundance biomarkers at levels down to femtograms/mL. This system assists clinicians in managing cardiovascular health, while also providing heart disease monitoring services and personalized wellness programs for patients. Singulex's offerings include ultra-sensitive immunoassay solutions and laboratory testing services that facilitate both reactive and proactive health management, as well as support the discovery of new therapeutics. The company serves a diverse clientele, including pharmaceutical research laboratories, clinical research organizations, and academic institutions globally. Additionally, Singulex is involved in pilot studies to validate its Erenna BioAssay System, which enhances molecular detection capabilities. Founded in 1997 and based in Alameda, California, Singulex has an additional office in Basel, Switzerland, and was previously known as BioProfile Corporation until its name change in 2003.
Alkahest, Inc. is a clinical stage biopharmaceutical company based in San Carlos, California, founded in 2014. The company focuses on developing therapies derived from blood to address neurological diseases, particularly those associated with aging, such as Alzheimer’s disease and Parkinson’s disease. Alkahest's research has revealed that factors present in the blood plasma of younger mice can potentially reverse cognitive deficits in aging and Alzheimer’s disease models. Collaborating with Grifols, a global healthcare company known for its plasma therapies, Alkahest aims to enhance health and vitality through innovative treatments that target the effects of aging.
Kiro Robotics is a technology company that specializes in the automation of machinery for the hospital sector. It concentrates on developing machines and equipment to automate and control key points of hospital processes, and hospital pharmacy processes in particular, improving the safety of patients and health professionals alike, and delivering increased efficiency.
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
VCN Biosciences is focused on researching and developing innovative treatments for tumors, particularly those that lack effective therapies. The company utilizes a specialized technological platform based on oncolytic adenoviruses, which are designed to selectively replicate and amplify within tumor cells. This approach aims to provide new therapeutic options for challenging cases, such as refractory tumors like pancreatic adenocarcinomas, thereby enhancing treatment possibilities for healthcare institutions.
Araclon Biotech is the scientific investigation, creation, explotation and comercialization of pharmacological and biotechnological products, and the making of diagnostic and pharmacological treatment models, and the explotation and comercialization of them, of owned or others' patents in that field, of the scientific lab activity, of investigation, and of investments in material and immaterial assets or so needed for the activity.
Talecris Biotherapeutics is a biopharmaceutical company based in Barcelona, Spain, specializing in the production and marketing of plasma-derived protein therapies. Founded in 2004, the company develops and distributes a range of therapies aimed at treating individuals with chronic and acute immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. Talecris offers hyperimmune therapies, which include antibody preparations for diseases such as hepatitis, rabies, and tetanus, as well as treatments for Rh-negative pregnant women carrying Rh-positive children. Additionally, the company provides albumin products under various brand names, including Plasbumin and Plasmanate, along with plasma-derived hemostasis products designed to assist patients lacking necessary clotting factors.
Celyad is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T NKR-2, C-Cure. The firm has CYAD-01, CYAD-02, CYAD-03 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.